[Eligibility of patients for CAR T-cell: Expert opinion-based collaborative work by the SFGM-TC].
Éligibilité des patients aux cellules CAR-T : avis d’experts proposé par la SFGM-TC.
Antigens, CD19
/ therapeutic use
Biological Products
Child
Europe
Humans
Immunotherapy, Adoptive
Lymphoma, Large B-Cell, Diffuse
/ therapy
Mediastinal Neoplasms
/ therapy
Patient Selection
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ therapy
Receptors, Antigen, T-Cell
/ therapeutic use
Receptors, Chimeric Antigen
Substance-Related Disorders
Young Adult
B-cell acute lymphoblastic leukemia
CAR T-cells
CD19
Cellules CAR-T
Diffuse large B-cell lymphoma
Leucémie aiguë lymphoblastique B
Lymphome diffus à grandes cellules B
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
Historique:
received:
10
06
2020
revised:
01
10
2020
accepted:
02
10
2020
pubmed:
12
1
2021
medline:
15
7
2021
entrez:
11
1
2021
Statut:
ppublish
Résumé
The chimeric antigen receptor T-cells are a new class of anticancer treatment consisting in genetically modifying autologous or allogenic T-cells to make express a CAR directed against a membrane tumor antigen. In Europe, tisagenlecleucel (Kymriah
Identifiants
pubmed: 33423776
pii: S0007-4551(20)30494-X
doi: 10.1016/j.bulcan.2020.10.017
pii:
doi:
Substances chimiques
Antigens, CD19
0
Biological Products
0
Receptors, Antigen, T-Cell
0
Receptors, Chimeric Antigen
0
tisagenlecleucel
Q6C9WHR03O
axicabtagene ciloleucel
U2I8T43Y7R
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
725-729Informations de copyright
Copyright © 2020 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.